Request a Call

Request a Call from a
representative

MED INFO LIVE CHAT

Chat with a medical
information specialist

Information for:

UK & IRELAND HEALTHCARE PROFESSIONALS

Click here if you are a healthcare professional and would like more information on Pradaxa® (dabigatran etexilate)


Information intended for:

PATIENTS PRESCRIBED PRADAXA®/ MEMBERS OF THE PUBLIC IN THE UK & IRELAND

Click here for more information on Pradaxa®


PC-GB -101423 V1 August 2020

The Right NOAC for the Right Patient –
Hear from our experts

Dr. Sarah Jarvis, a London-based GP with a special interest in cardiology, joined Professor Terry McCormack, a GP and Honorary Professor in Primary Care Cardiovascular Medicine at the Hull York Medical School, to discuss how bleeding risk should influence your treatment decision-making for stroke prevention in non-valvular atrial fibrillation (NVAF).

Introducing Jenny, Tom and Adhar, our experts use these patient examples to determine the key factors when considering treatment options for stroke prevention in patients with NVAF. These include:

  • The role of CHA2DS2-VASc and HAS-BLED in determining stroke and bleeding risk
  • What the guidelines recommend for managing anticoagulation for stroke prevention in patients with NVAF, particularly in light of the COVID-19 pandemic
  • There are four currently available non-vitamin K antagonist oral anticoagulants (NOACs), with different criteria for dose reduction
  • A review of the number of patients on low-dose NOACs in clinical trials and the percentage of real-world prescriptions of low-dose NOACs in the UK
  • The efficacy and safety outcomes for the low-dose NOACs in the pivotal Phase III clinical trials comparing NOACs vs warfarin
  • The availability of a specific reversal agent for emergency surgery or life-threatening bleeding.

 

Below, hear our experts outline why not all patients with NVAF are the same and the need for a tailored approach to stroke prevention.

Abbreviations

NOAC — non-vitamin K antagonist oral anticoagulant

NVAF — non-valvular atrial fibrillation

PC-GB-102475 V1 | December 2020

Disclaimer

You are about to leave the Boehringer Ingelheim site for a site not created, managed or maintained by Boehringer Ingelheim.

Boehringer Ingelheim hopes that this link will be of interest and use to visitors, but it accepts no liability in relation to the website or its contents and gives no warranty as to the accuracy or completeness of information, data or reports on the website, to the fullest extent that any such liability may be lawfully excluded. Nor does Boehringer Ingelheim necessarily endorse or support any content on the third party website or any further links from their website.